Alpelisib Plus Cetuximab may be Effective for Patients with Cetuximab-Resistant Head and Neck Cancer
the Cancer Therapy Advisor take:
According to new findings presented at the American Association for Cancer Research (AACR) special conference Targeting the PI3K-mTOR Network in Philadelphia, Pennsylvania, alpelisib, also known as BYL719, was an effective treatment in combination with cetuximab in patients with cetuximab-resistant head and neck cancer.
In the phase 1b study, researchers enrolled 37 patients with recurrent or metastatic squamous cell carcinoma of the head and neck with previous resistance to platinum-based chemotherapy. Of those, five patients took alpelisib 400 mg once daily plus cetuximab and 32 patients took alpelisib 300 mg once daily alone.
Among all patients, the overall response rate was 11% with a 54% disease control rate. Of the patients that received alpelisib alone, four patients achieved a confirmed partial response and 16 patients had stable disease. In addition, one of the seven patients who had relapsed on prior cetuximab therapy achieved a partial response and five had disease control.
Based on the results of this study, researchers are currently conducting a phase 2 trial to study alpelisib 300 mg once daily in combination with cetuximab in patients with squamous cell carcinoma of the head and neck.
BYL719, an effective treatment in combination with cetuximab in patients head and neck cancer.
The investigational drug alpelisib, previously known as BYL719, was able to overcome head and neck cancer resistance to the anti-EGFR treatment cetuximab, and combining alpelisib with cetuximab was found to be beneficial, according to data from a phase Ib/II trial presented at the AACR special conference Targeting the PI3K-mTOR Network in Cancer, held Sept. 14-17.
"Most of head and neck cancers are driven by activation of the EGFR pathway. Cetuximab is a drug that targets EGFR and is effective in this setting, but cancers often become resistant to this therapy," said Pamela Munster, MD, professor of medicine and director of the Early Phase Clinical Trials Unit at the UCSF Helen Diller Family Comprehensive Cancer Center. "Treatment resistance is often conveyed through activation of the PI3K/AKT/mTOR pathway, and alpelisib is an inhibitor of this pathway."
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
- BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
- Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer